Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.
about
Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR ImagingCurrent standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsImaging biomarkers for antiangiogenic therapy in malignant gliomas.Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging.Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI.Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria)Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumabAssessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Multi-modal imaging of tumor cellularity and Tryptophan metabolism in human Gliomas.Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.Multiparametric MRI and [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging Is a Potential Prognostic Imaging Biomarker in Recurrent Glioblastoma.Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM.Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.Early response evaluation for recurrent high grade gliomas treated with bevacizumab: a volumetric analysis using diffusion-weighted imaging.The Added Prognostic Value of Metabolic Tumor Size on FDG-PET at First Suspected Recurrence of Glioblastoma Multiforme.Brain metastases: neuroimaging.Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous 18F-FDG-PET/MRI: A Single-Institution Retrospective Study.Bevacizumab: radiation combination produces restricted diffusion on brain MRI.Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.Conventional and advanced magnetic resonance imaging in patients with high grade glioma.[Towards more precision in the therapy of brain tumors. Possibilities and limits of MRI].Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab.
P2860
Q26796223-80108C6A-6F92-4449-8232-9A756BE6FDE0Q26853308-2C4E281B-A351-4864-A935-D530490187C3Q30764736-B7A24A3E-AEAB-49A1-854F-05E6DE092DEEQ30847288-62B4634C-CE38-4D8E-8DFB-897F3A02D7DDQ31121795-C89B0CB5-F833-4926-9304-B48F6F0A42D9Q33649467-10E47E55-775F-4C3B-AD76-635D0157BE59Q34511741-57132359-7511-4F7E-874E-6138F46033E3Q35028897-6B98B1E2-3006-4DC7-B257-9DEA97029EB2Q35156040-3FDED240-82A0-4250-BD7F-9CC6BA0739F5Q35771783-4B70378B-1705-44E7-8C9E-3707B3CD8F1DQ35895174-C412577F-A37E-4B0B-9946-CFD9AD7BBC9FQ35923158-D31D3F5C-3A93-4E8B-87B6-EF301445FACCQ36427538-E1CC15C7-C806-4A93-A1CD-84DDEB41E016Q36785131-579CDECE-8055-49C6-BD7F-A0CEAC483C12Q37510450-D685E5A6-A45E-4972-AD39-BDA84A618B18Q37586118-F1D1B653-6BCC-4294-A43A-4D40EBBAFA58Q38958800-D66027FE-32DE-4754-822D-DB88DFDCFEBFQ39030177-14252741-B096-41DA-8F9A-219D1DA62741Q39225820-5A89D90F-733D-4607-B3EA-86950C12090AQ41462863-D5ECB213-09B5-46EC-895F-243027DDFE76Q42963891-29F7DBC3-B940-4384-87E6-0D6A3C35EB1BQ44362904-03EF5FC5-7D2A-4B92-81D8-D01EB3DA3D28Q45951765-080EF533-E7E8-42AE-85E6-7D17B00E6CDCQ47281917-8EBF1B33-7EDC-41CE-98F1-250F667FF6BBQ47879878-0CF59358-B318-4428-B3F1-0710AC6EF8EAQ48245198-40AB05E6-12F1-4312-AA39-278F591FD683Q48246048-D9428962-244C-4138-8787-AF078ABD02CDQ48468668-4C7A1C71-C09F-4AA7-A3D0-3BCC57FFD6C1Q49499240-F3770D7C-9F01-4EC5-9036-7AE56891155EQ52562075-0567BCE7-5561-4661-B27F-ADA2C922E051Q53491303-9ED2CDDF-6AEA-4FDA-8EF6-8139F6EEFFA6Q55035317-2E901DAF-EC6F-4463-9FB9-1C4AB26F55D6
P2860
Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Persistent diffusion-restricte ...... ompared with matched controls.
@en
Persistent diffusion-restricte ...... ompared with matched controls.
@nl
type
label
Persistent diffusion-restricte ...... ompared with matched controls.
@en
Persistent diffusion-restricte ...... ompared with matched controls.
@nl
prefLabel
Persistent diffusion-restricte ...... ompared with matched controls.
@en
Persistent diffusion-restricte ...... ompared with matched controls.
@nl
P2093
P2860
P356
P1476
Persistent diffusion-restricte ...... compared with matched controls
@en
P2093
B M Ellingson
L Mirsadraei
P L Nghiemphu
T F Cloughesy
P2860
P304
P356
10.3174/AJNR.A3053
P50
P577
2012-04-26T00:00:00Z